Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 8/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.46 |
| ▸ | PDE4A | P27815 | 5/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890674 | 0.92 | PDE3B (0.45) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL5630424 | 0.89 | LMNA (0.59) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL8348201 | 0.85 | PDE3B (0.48) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL4890649 | 0.84 | LMNA (0.45) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL4894708 | 0.84 | LMNA (0.45) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL8266689 | 0.83 | LMNA (0.44) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL4890576 | 0.82 | PDE3B (0.54) | PDE3BPDE3APDE4BPDE4APDE4C | |
| SCHEMBL4884907 | 0.81 | ADRB1 (0.48) | PDE4DLMNANPY1RNPY2RMAPT | |
| SCHEMBL4888940 | 0.81 | LMNA (0.42) | LMNANPY1RNPY2RMAPTHRH3 | |
| SCHEMBL7327893 | 0.81 | PDE3B (0.52) | PDE3BPDE3APDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| EP-1830852-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | Artesian Therapeutics, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006060127-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006060127-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ADRB3, PDE3A, PDE3B | PDE3B 3/4885PDE3A 2/4885PDE4B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.